Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
出版年份 2018 全文链接
标题
Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
作者
关键词
-
出版物
Expert Review of Respiratory Medicine
Volume -, Issue -, Pages 1-12
出版商
Informa UK Limited
发表日期
2018-12-31
DOI
10.1080/17476348.2019.1563488
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma
- (2018) Shingo Inaguma et al. HUMAN PATHOLOGY
- Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.
- (2018) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma
- (2018) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma
- (2018) Fausto Petrelli et al. RESPIRATORY MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
- (2018) Anna K. Nowak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).
- (2018) Arpita Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma
- (2018) Surein Arulananda et al. Journal of Thoracic Oncology
- Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection
- (2018) Vivek Verma et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Prospect of rindopepimut in the treatment of glioblastoma
- (2017) Aladine A. Elsamadicy et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
- (2017) Raffit Hassan et al. Journal of Thoracic Oncology
- MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
- (2017) Y. Goto et al. Journal of Thoracic Oncology
- OA13.02 Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis
- (2017) Hedy Kindler et al. Journal of Thoracic Oncology
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Amatuximab and novel agents targeting mesothelin for solid tumors
- (2017) Paolo Baldo et al. OncoTargets and Therapy
- Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
- (2017) Takashi Eguchi et al. Oncotarget
- The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
- (2017) Christian M. Schürch et al. OncoImmunology
- Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
- (2016) Robin Cornelissen et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
- (2016) Jae H. Park et al. BLOOD
- CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor
- (2016) Silvio Roncella et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN Combined with Chemotherapy
- (2016) D. H. Sterman et al. CLINICAL CANCER RESEARCH
- Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas
- (2016) Christelle Combaz-Lair et al. HUMAN PATHOLOGY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Malignant Mesothelioma Effusions Are Infiltrated by CD3 + T Cells Highly Expressing PD-L1 and the PD-L1 + Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab
- (2016) Swati Khanna et al. Journal of Thoracic Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
- (2016) M. M. Awad et al. Cancer Immunology Research
- Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
- (2016) Elly Marcq et al. OncoImmunology
- Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
- (2016) Tuuli Ranki et al. Journal for ImmunoTherapy of Cancer
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study
- (2015) Marco Lo Iacono et al. Journal of Thoracic Oncology
- Intratumoral macrophage phenotype and CD8 + T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma
- (2015) Robin Cornelissen et al. LUNG CANCER
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Reactive oxygen species a double-edged sword for mesothelioma
- (2015) Serena Benedetti et al. Oncotarget
- CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
- (2015) Luis H. Camacho Cancer Medicine
- Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
- (2015) Luana Calabrò et al. Lancet Respiratory Medicine
- Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen
- (2015) Jenette Creaney et al. OncoImmunology
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
- (2015) Susana Cedrés et al. PLoS One
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
- (2014) M. Rajasagi et al. BLOOD
- Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
- (2014) G. Guo et al. CANCER RESEARCH
- Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
- (2014) R. Hassan et al. CLINICAL CANCER RESEARCH
- B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
- (2014) Aaron Scott Mansfield et al. Journal of Thoracic Oncology
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
- (2014) Mahesh Yadav et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
- (2014) Robin Cornelissen et al. PLoS One
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer
- (2013) Darin A. Wick et al. CLINICAL CANCER RESEARCH
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation
- (2012) B. M. Burt et al. CLINICAL CANCER RESEARCH
- Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma
- (2011) Bryan M. Burt et al. CANCER
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
- (2011) Caroline J. Breitbach et al. NATURE
- The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
- (2011) Matthew Bott et al. NATURE GENETICS
- Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma
- (2010) Joost P. Hegmans et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
- (2010) H Li et al. CANCER GENE THERAPY
- WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
- (2010) Lee M. Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
- (2010) Vincenzo Cerullo et al. CANCER RESEARCH
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
- (2010) Anniina Koski et al. MOLECULAR THERAPY
- Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma
- (2009) Marc de Perrot et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma
- (2009) Lee M. Krug et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy
- (2009) Servet Bölükbas et al. LUNG CANCER
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response
- (2008) A. Gauvrit et al. CANCER RESEARCH
- Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
- (2008) Masaki Anraku et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Pathology of mesothelioma
- (2008) Kouki Inai Environmental Health and Preventive Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now